A Survey of Cannabigerol User’s Patterns of Use, Perceived Efficacy and Satisfaction

{"Cannabigerol":[0],"(CBG)":[1],"and":[2,16,69,94,122,151,164],"the":[3,55,189],"acidic":[4],"form":[5],"of":[6,28,49,96,146,149,161,178,191],"CBG":[7,150,179,192],"(cannabigerolic":[8],"acid,":[9],"CBGA)":[10],"are":[11],"becoming":[12],"increasingly":[13],"more":[14,197],"available":[15],"popular,":[17],"with":[18,71,127],"pre-clinical":[19],"rodent":[20],"research":[21],"suggesting":[22],"these":[23,75,166],"compounds":[24],"have":[25,33],"an":[26],"array":[27],"therapeutic":[29],"effects.":[30,98],"However,":[31],"there":[32],"been":[34],"few":[35],"clinical":[36,185],"trials":[37,186],"or":[38],"surveys":[39],"examining":[40],"their":[41,66,81,88,138],"effects":[42,157,167,190],"in":[43,195],"humans.":[44],"We":[45],"conducted":[46],"a":[47,144,196],"survey":[48],"239":[50],"CBG/CBGA":[51,60,72,106,132],"users":[52],"to":[53,61,91,107,135,187],"assess":[54],"medical":[56],"conditions":[57,102],"they":[58,152,155],"use":[59,83],"manage,":[62],"as":[63,65,180,182],"well":[64,181],"perceived":[67,89],"efficacy":[68],"satisfaction":[70],"for":[73,169],"managing":[74],"conditions.":[76],"Participants":[77,140],"also":[78],"reported":[79,104,141],"on":[80,193],"typical":[82,86],"patterns":[84],"(e.g.":[85],"dose),":[87],"time":[90],"feel":[92,156],"effects,":[93],"duration":[95],"those":[97],"The":[99],"top":[100],"five":[101],"participants":[103,128],"using":[105,143],"manage":[108],"were":[109],"insomnia/disturbed":[110],"sleep":[111],"(62%),":[112],"inflammatory":[113],"chronic":[114,124],"pain":[115,120,125],"(44%),":[116],"anxiety":[117],"(33%),":[118],"episodic":[119],"(29%),":[121],"neuropathic":[123],"(28%),":[126],"generally":[129],"reporting":[130],"that":[131,154,165],"\\"slightly":[133],"improves\\"":[134,137],"\\"much":[136],"symptoms.":[139],"typically":[142],"dose":[145],"10-12":[147],"mg":[148],"indicated":[153],"within":[158],"15-60":[159],"min":[160],"oral":[162],"ingestion":[163],"persist":[168],"4-6":[170],"h.":[171],"These":[172],"findings":[173],"will":[174],"help":[175],"inform":[176],"consumers":[177],"researchers":[183],"designing":[184],"investigate":[188],"humans":[194],"objective":[198],"manner.":[199]}

Authors

Institutions

Publication Details

Journal
Journal of Psychoactive Drugs
Published
2026-09-15
DOI
https://doi.org/10.1080/02791072.2026.2727651
Primary Topic
Pharmacological Effects and Assays
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

A Survey of Cannabigerol User’s Patterns of Use, Perceived Efficacy and Satisfaction

Carrie Cuttler, Dustin Sulak, E. T. Lutz, Leigh Vinocur et al.
Journal of Psychoactive Drugs
Pharmacological Effects and Assays
article

A Survey of Cannabigerol User’s Patterns of Use, Perceived Efficacy and Satisfaction

Carrie Cuttler, Dustin Sulak, E. T. Lutz, Leigh Vinocur, Ethan B. Russo
article en

Abstract

Cannabigerol (CBG) and the acidic form of CBG (cannabigerolic acid, CBGA) are becoming increasingly more available and popular, with pre-clinical rodent research suggesting these compounds have an array of therapeutic effects. However, there have been few clinical trials or surveys examining their effects in humans. We conducted a survey of 239 CBG/CBGA users to assess the medical conditions they use CBG/CBGA to manage, as well as their perceived efficacy and satisfaction with CBG/CBGA for managing these conditions. Participants also reported on their typical use patterns (e.g. typical dose), their perceived time to feel effects, and duration of those effects. The top five conditions participants reported using CBG/CBGA to manage were insomnia/disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%), and neuropathic chronic pain (28%), with participants generally reporting that CBG/CBGA "slightly improves" to "much improves" their symptoms. Participants reported typically using a dose of 10-12 mg of CBG and they indicated that they feel effects within 15-60 min of oral ingestion and that these effects persist for 4-6 h. These findings will help inform consumers of CBG as well as researchers designing clinical trials to investigate the effects of CBG on humans in a more objective manner.

Journal of Psychoactive Drugs
Hess (United States) (US), Credo Reference (United States) (US), Directorate of Medicinal and Aromatic Plants Research (IN), Washington State University (US)
Good health and well-being
Openalex Percentile: Top 14%
Pharmacological Effects and Assays
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.